Results of the German IPEP study evaluating the tolerability, efficacy, and acceptance of fulvestrant (FASLODEX (R)) under routine clinical conditions in advanced breast cancer
Document type:
Meeting Abstract
Author(s):
Warm, M; Thomas, A; Ziegler, K; Kates, R; Overkamp, F; Harbeck, N